Furthermore, Benyamine et al. demonstrated that the use of BTN3A1 can improve the Vγ9Vδ2 T-cells-based immunotherapy of acute myeloid leukemia [162]. This evidence concerns the gene BTN3A1 and acute myeloid leukemia.